Trial: 202101066

EMBER-2: A Phase 1, Open-Label, Preoperative Window Study evaluating the Biological Effects of LY3484356 in Post-menopausal Women with Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Phase

I

Principal Investigator

Aft, Rebecca

Disease Site

Breast

Learn more about this study at: clinicaltrials.gov